Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8026 to 8040 of 8905 results

  1. Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  2. Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy statement on biologic therapies for the treatment of juvenile idiopathic arthritis is available.

    Withdrawn advice

  3. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Withdrawn advice

  4. Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

    This evidence summary has been updated and replaced by the NICE guideline CG178 (published February 2014).

    Withdrawn advice

  5. Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  6. Induction of labour: misoprostol vaginal delivery system (ESNM38)

    We withdrew this evidence summary in May 2021 because the manufacturer has discontinued the product.

    Withdrawn advice

  7. Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)

    This evidence summary has been replaced by the long-acting reversible contraception: implementation resource summary.

    Withdrawn advice

  8. Type 2 diabetes: insulin degludec (ESNM4)

    This evidence summary has been updated and replaced by NICE advice ESNM25.

    Withdrawn advice

  9. Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  10. Psoriatic arthritis in adults: certolizumab pegol (ESNM42)

    This evidence summary has been updated and replaced by NICE technology appraisal guidance 445.

    Withdrawn advice

  11. Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  12. Type 1 diabetes: insulin degludec (ESNM5)

    This evidence summary has been updated and replaced by NICE advice ESNM24.

    Withdrawn advice

  13. Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)

    This evidence summary has been updated and replaced by NICE guideline NG203.

    Withdrawn advice

  14. Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice

  15. Asthma: tiotropium (Spiriva Respimat) (ESNM55)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Withdrawn advice